Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinemic pre-menopausal women

European Journal of Endocrinology

Volumn 149, Issue 3, 2003, Pages 187-193

  Yavuz, Dilek ^b   Deyneli, Oǧuzhan ^b   Akpinar, Ihsan ^a   Yildiz, Erdem ^a   Gözü, Hülya ^b   Sezgin, Özlem ^b   Haklar, Goncagül ^a   Akalin, Sema ^b  

^a MARMARA UNIVERSITY   (Turkey)

^b Section of Endocrinology/Metabolism   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; C REACTIVE PROTEIN; ESTROGEN; FIBRINOGEN; GLUCOSE; HOMOCYSTEINE; INSULIN; PROLACTIN; URIC ACID;

ADULT; ARTERY BLOOD FLOW; ARTERY DILATATION; ARTICLE; ATHEROSCLEROSIS; BLOOD FLOWMETRY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DRUG DOSE REGIMEN; DRUG EFFICACY; ENDOTHELIUM; ESTROGEN BLOOD LEVEL; FEMALE; FIBRINOGEN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSIS ADENOMA; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; ORAL GLUCOSE TOLERANCE TEST; PREMENOPAUSE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; URIC ACID BLOOD LEVEL;

ADULT; BLOOD GLUCOSE; BROMOCRIPTINE; C-REACTIVE PROTEIN; CHOLESTEROL; ENDOTHELIUM, VASCULAR; ESTROGENS; FEMALE; FIBRINOGEN; GLUCOSE TOLERANCE TEST; HOMOCYSTEINE; HORMONE ANTAGONISTS; HUMANS; HYPERPROLACTINEMIA; INSULIN; INSULIN RESISTANCE; PREMENOPAUSE; PROLACTIN; URIC ACID; VASODILATION;

EID: 0141627777     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1490187     Document Type: Article

References (28)

1. Reis FM, Reis AM & Coimbra CC. Effects of hyperprolactinemia on glucose tolerance and insulin release in male and female rats. Journal of Endocrinology 1977 153 423-428.
2. Matsuda M & Mori T. Effect of estrogen on hyperprolactinemia-induced glucose intolerance in SHN mice. Proceedings of the Society for Experimental Biology and Medicine 1996 212 243-247.
3. Landgraf R, Landraf-Leurs MM, Weissmann A, Horl R, von Werder K & Scriba PC. Prolactin: a diabetogenic hormone. Diabetologia 1977 13 99-104.
4. Serri O, Beauregard H, Rasio E & Hardy J. Decreased sensitivity to insulin in women with microprolactinomas. Fertility and Sterility 1986 45 572-574.
5. Seki K & Nagata I. Levels of glucose and insulin during twenty-four hours in hyperprolactinemic women with pituitary microadenoma. Gynecology and Obstetrics Investigations 1991 31 222-225.
6. Gustafson AB, Banasiak MF, Kalkhoff RK, Hagen TC & Kim HJ. Correlation of hyperprolactinemia with altered plasma insulin and glucagon: similarity to effects of late human pregnancy. Journal of Clinical Endocrinology and Metabolism 1980 51 242-246.
7. Foss MC, Paula FJ, Paccola GM & Piccinato CE. Peripheral glucose metabolism in human hyperprolactinemia. Clinical Endocrinology 1995 43 721-726.
8. Schernthaner G, Prager R, Punzengruber C & Luger A. Severe hyperprolactinemia is associated with decreased insulin binding in vitro and insulin resistance in vivo. Diabetologia 1985 28 138-142.
9. Sorenson RL, Brelje TC, Hegre OD, Marshall S, Anaya P & Sheridan JD. Prolactin (in vitro) decreases the glucose stimulation threshold, enhances insulin secretion and increases dye coupling among islet beta cells. Endocrinology 1987 121 1447-1453.
10. Matsuda M & DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing. Diabetes Care 1999 22 1462-1470.
11. Matthews DR, Hosker JT, Rudenski AS, Naylor BA, Treacher DF & Turner RC. Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 412-419.
12. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992 340 1111-1115.
13. Ferrannini E & Mari A. How to measure insulin sensitivity. Journal of Hypertension 1998 16 895-906.
14. Nielsen JH. Effects of growth hormone, prolactin and placental lactogen on insulin content and release and deoxyribonucleic acid synthesis in cultured pancreatic islets. Endocrinology 1982 110 600-608.
15. Hoiriis Nielsen J, Nielsen V, Molsted Pedersen L & Deckert T. Effects of pregnancy hormones on pancreatic islets in organ culture. Acta Endocrinologica 1986 111 336-341.
16. Pijl H, Ohashi S, Matsuda M, Miyazaki Y, Mahankali A, Kumar V et al. Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care 2000 23 1154-1161.
17. Mather KJ, Verma S, Corenblum B & Anderson TJ. Normal endothelial function despite insulin resistance in healthy women with the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2000 85 1851-1856.
18. Higashi Y, Sanada M, Sasaki S, Nakagawa K, Goto C, Matsuura H et al. Effect of estrogen replacement therapy on endothelial function in peripheral resistance arteries in normotensive and hypertensive postmenopausal women. Hypertension 2001 7 651-657.
19. Zeiher AM, Drexler H, Wollschlager H & Just H. Endothelial dysfunction of the coronary microvasculature is associated with coronary blood flow regulation in patients with early atherosclerosis. Circulation 1991 84 1984-1992.
20. Deedwania PC. Endothelium: a new target for cardiovascular therapeutics. Journal of the American College of Cardiology 2000 35 67-70.
21. Ross R. Atherosclerosis an inflammatory disease. New England Journal of Medicine 1999 340 115-126.
22. Cleland SJ, Sattar N, Petrie JR, Forouhi NG, Elliott HL & Connell JM. Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. Clinical Science 2000 98 531-535.
23. Fichtlscherer S, Rosenberger G, Walter DH, Breuer S, Dimmeler S & Zeiher AM. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 2000 102 1000-1006.
24. Herrmann W. The importance of hyperhomocysteinemia as a risk factor for diseases: an overview. Clinical Chemistry and Laboratory Medicine 2001 39 666-674.
25. Fonseca V, Guba SC & Fink LM. Hyperhomocysteinemia and the endocrine system, implications for atherosclerosis and thrombosis. Endocrine Reviews 1999 20 738-759.
26. Meigs JB, Jacques PF, Selhub J, Singer DE, Nathan DM, Rifai N et al. Fasting plasma homocysteine levels in the insulin resistance syndrome: the Framingham Offspring Study. Diabetes Care 2001 24 1403-1410.
27. Bar-On H, Kidron M, Friedlander Y, Ben-Yehuda A, Selhub J, Rosenberg IH et al. Plasma total homocysteine levels in subjects with hyperinsulinemia. Journal of Internal Medicine 2000 247 287-294.
28. De Pergola G, Pannacciulli N, Zamboni M, Minenna A, Brocco G, Sciaraffia M et al. Homocysteine plasma levels are independently associated with insulin resistance in normal weight, overweight and obese premenopausal women. Diabetes, Nutrition and Metabolism 2001 14 253-258.